Sumary of In vivo protection from emerging SARS-CoV-2 variants by protein nanoparticle vaccine:
- Researchers in the United States have developed a new coronavirus disease 2019 (COVID-19) vaccine that induced potent neutralizing antibodies against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in animal models..
- The team developed a recombinant SARS-CoV-2 spike protein antigen containing mutations from the B.1.351 variant (Beta) that emerged in South Africa..
- in Gaithersburg, Maryland, have shown that a recombinant spike protein (rS) antigen contains B.1.351 mutations (rS-B.1.351) protected mice against infection with B.1.351..
- The vaccine also protected the animals against the B.1.1.7 variant that emerged in the UK and the original SARS-CoV-2 strain identified in Wuhan (Wuhan-Hu-1 strain)..
- Furthermore, a robust anamnestic response was observed among baboons that were boosted with rS-B.1.351 approximately one year following immunization with a prototype vaccine the team previously developed that was based on the Wuhan-Hu-1 strain..
- James Logue and colleagues say this points to the feasibility of using the vaccine as a booster following previous immunization with vaccines developed against the ancestral SARS-CoV-2 spike protein..
- As a result of the continued global spread of SARS-CoV-2, several variant strains containing mutations have emerged, increasing transmissibility and conferring resistance to vaccination and infection..
- While the B.1.1.7 variant )Alpha) is more transmissible compared with ancestral strains and has caused more hospitalizations globally, it is still effectively targeted by vaccine or infection-induced immunity and currently authorized monoclonal antibodies….